Zobrazeno 1 - 10
of 3 732
pro vyhledávání: ''
Autor:
Julia W, Gargano, Nancy, McClung, Rayleen M, Lewis, Ina U, Park, Erin, Whitney, Jessica L, Castilho, Manideepthi, Pemmaraju, Linda M, Niccolai, Monica, Brackney, Emilio, DeBess, Sara, Ehlers, Nancy M, Bennett, Mary, Scahill, Angela A, Cleveland, Troy D, Querec, Elizabeth R, Unger, Lauri E, Markowitz
Publikováno v:
International Journal of Cancer. 152:137-150
Declines in cervical intraepithelial neoplasia grades 2 to 3 and adenocarcinoma in situ (CIN2+) observed among young women suggest impact from human papillomavirus (HPV) vaccination. To further evaluate vaccine impact including cross-protection and t
Autor:
Fangcheng Yuan, Ruth M. Pfeiffer, Sachelly Julián‐Serrano, Simran Arjani, Michael J. Barrett, Jill Koshiol, Rachael Z. Stolzenberg‐Solomon
Publikováno v:
International Journal of Cancer. 152:172-182
Pancreatic cancer (PC) is highly fatal, and its incidence is increasing in the United States. Population-based registry studies suggest associations between a few autoimmune conditions and PC risk, albeit based on a relatively small number of cases.
Publikováno v:
International Journal of Cancer. 151:1960-1968
We investigated if female survival advantage trends in cancer are consistent within Jordanian patients with cancer across different age groups and nonsex specific cancer types. We explored the King Hussein Cancer Center registry for primary malignant
Publikováno v:
International Journal of Cancer. 151:1216-1227
Immunity may play a role in preventing cancer progression. We studied associations of immune-related conditions with cancer-specific mortality among older adults in the United States. We evaluated 1 229 443 patients diagnosed with 20 common cancer ty
Autor:
Karlijn L. van Rooijen, Jeroen W. G. Derksen, Helena M. Verkooijen, Geraldine R. Vink, Miriam Koopman
Publikováno v:
International Journal of Cancer. 151:1270-1279
The IDEA trial showed no clinical relevant differences in efficacy between 3 and 6 months of oxaliplatin-based adjuvant chemotherapy (ACT) in colon cancer (CC), while toxicity was substantially lower in the 3 months regimen. Therefore, in 2017 the Du
Autor:
Eleni M. Rettig, Daniel L. Faden, Shaiba Sandhu, Kristine Wong, William C. Faquin, Chloe Warinner, Phil Stephens, Sunil Kumar, Charlotte Kuperwasser, Jeremy D. Richmon, Ravindra Uppaluri, Mark Varvares, Rosh Sethi, Glenn J. Hanna, Herve Sroussi
Publikováno v:
International Journal of Cancer. 151:1081-1085
Human papillomavirus (HPV), most commonly HPV16, causes a growing subset of head and neck squamous cell carcinomas (HNSCCs), including the overwhelming majority of oropharynx squamous cell carcinomas in many developed countries. Circulating biomarker
Autor:
Juan Vaz, Patrik Midlöv, Malin Sternby Eilard, Berne Eriksson, David Buchebner, Ulf Strömberg
Publikováno v:
International Journal of Cancer. 151:229-239
Contemporary European studies examining associations between socioeconomic status and hepatocellular carcinoma (HCC) incidence are scarce. We aimed to target population groups with a heavier burden of HCC by assessing associations of individual-level
Publikováno v:
International Journal of Cancer. 150:1760-1769
Our study measures the impact of diagnosing cancers early before they metastasise on reducing the burden of cancer death. A cohort of 716 501 people aged 15 to 89 years diagnosed with a solid cancer in New South Wales, Australia, during 1985 to 2014
Autor:
Stefanie D. Krens, Wim van Boxtel, Carla M.L. van Herpen, Sasja F. Mulder, Frank G A Jansman, Maike J. M. Uijen, Ingrid M.E. Desar, Nielka P. van Erp
Publikováno v:
International Journal of Cancer, 150, 308-316
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
Contains fulltext : 249093.pdf (Publisher’s version ) (Open Access) Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has
Autor:
John B. A. G. Haanen, Maureen J.B. Aarts, Michel W.J.M. Wouters, Albert J. ten Tije, Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Rozemarijn S. van Rijn, Alfons J.M. van den Eertwegh, Liesbeth C. de Wreede, Ellen Kapiteijn, Geke A. P. Hospers, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, Gerard Vreugdenhil, Michiel C T van Zeijl, Jan-Willem B de Groot, Djura Piersma
Publikováno v:
International Journal of Cancer, 150(2), 317-326. Wiley-Liss Inc.
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800
Contains fulltext : 287666.pdf (Publisher’s version ) (Open Access) There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti-PD-1 discontinuation,